Mazdutide (TFA)

Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR) . Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM) . Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) [1][2][3].

Product Specifications

Product Name Alternative

IBI-362 (TFA) ; LY-3305677 (TFA) ; OXM-3 (TFA)

UNSPSC

12352209

Target

GCGR; GLP Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/mazdutide-tfa.html

Purity

99.67

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

[Mazdutide(TFA)]

Molecular Formula

C210H322N46O67.xC2HF3O2

Molecular Weight

4563.06 (free base)

References & Citations

[1]Chen T, et al. The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. J Med Chem. 2022 Mar 10;65 (5) :3685-3705.|[2]Jiang H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13 (1) :3613.|[3]Chen Y, Mezo A, Coskun T, et al. 682-P: novel dual glucagon and glucagon-like peptide-1 receptor agonist LY3305677 improves glucose control, reduces body weight, and increases energy expenditure in mice[J]. Diabetes, 2021, 70 (Supplement_1) .